Meningococcal vaccines

Pediatric Drugs

Volumn 6, Issue 4, 2004, Pages 251-266

  Rüggeberg, Jens U ^a   Pollard, Andrew J ^b,c  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BACTERICIDE; MEMBRANE PROTEIN; MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; PORIN B; RECOMBINANT PROTEIN; TRANSFERRIN BINDING PROTEIN A; TRANSFERRIN BINDING PROTEIN B; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIGENICITY; BACTERIAL COLONIZATION; BRONCHOSPASM; CLINICAL TRIAL; CONVULSION; CORRELATION ANALYSIS; DIZZINESS; DRUG CONJUGATION; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; EPIDEMIC; ERYTHEMA; EUROPE; FACE EDEMA; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC CONSERVATION; GENETIC POLYMORPHISM; GENETIC RECOMBINATION; GENETIC VARIABILITY; HEADACHE; HEALTH SURVEY; HUMAN; HYPERSENSITIVITY; HYPESTHESIA; IMMUNOGENICITY; INCIDENCE; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; LYMPHADENOPATHY; MALAISE; MENINGOCOCCOSIS; MORTALITY; MUSCLE HYPOTONIA; NAUSEA; NEISSERIA; NEISSERIA LACTAMICA; NEISSERIA MENINGITIDIS; NONHUMAN; PARESTHESIA; PATHOGENESIS; POPULATION RESEARCH; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; RISK FACTOR; SEQUENCE ANALYSIS; SEROTYPING; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYNCOPE; UNITED KINGDOM; UNITED STATES; URTICARIA; VOMITING;

ADOLESCENT; CHILD, PRESCHOOL; CLINICAL TRIALS; HUMANS; INFANT; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP C; RISK FACTORS;

EID: 6044246245     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200406040-00004     Document Type: Review

References (216)

1. Gotschlich EC, Liu TY, Artenstein MS. Human immunity to the meningococcus: 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides. J Exp Med 1969; 129 (6): 1349-65
2. Maiden MC, Bygraves JA, Feil E, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 1998; 95 (6); 3140-5
3. Yakubu DE, Abadi FJ, Pennington TH. Molecular typing methods for Neisseria meningitidis. J Med Microbiol 1999; 48 (12): 1055-64
4. Jolley KA, Kalmusova J, Feil EJ, et al. Carried meningococci in the Czech Republic: a diverse recombining population. J Clin Microbiol 2000; 38 (12): 4492-8
5. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus: II. Development of natural immunity. J Exp Med 1969; 129 (6): 1327-48
6. Jones GR, Christodoulides M, Brooks JL, et al. Dynamics of carriage of Neisseria meningitidis in a group of military recruits: subtype stability and specificity of the immune response following colonization. J Infect Dis 1998; 178 (2): 451-9
7. Cartwright KA, Stuart JM, Jones DM, et al. The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol Infect 1987; 99 (3): 591-601
8. Trotter CL, Gay NJ. Analysis of longitudinal bacterial carriage studies accounting for sensitivity of swabbing: an application to Neisseria meningitidis. Epidemiol Infect 2003; 130 (2): 201-5
9. Jordens JZ, Williams JN, Jones GR, et al. Detection of meningococcal carriage by culture and PCR of throat swabs and mouth gargles. J Clin Microbiol 2002; 40 (1): 75-9
10. Sim RJ, Harrison MM, Moxon ER, et al. Underestimation of meningococci in tonsillar tissue by nasopharyngeal swabbing. Lancet 2000; 356 (9242): 1653-4
11. Cardenosa N, Dominguez A, Orcau A, et al. Carriers of Neisseria meningitidis in household contacts of meningococcal disease cases in Catalonia (Spain). Eur J Epidemiol 2001; 17 (9): 877-84
12. Tyrrell GJ, Chui L, Johnson M, et al. Outbreak of Neisseria meningitidis, Edmonton, Alberta, Canada. Emerg Infect Dis 2002; 8 (5): 519-21
13. Caugant DA, Hoiby EA, Magnus P, et al. Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J Clin Microbiol 1994; 32 (2): 323-30
14. Ala'Aldeen DA, Neal KR, Ait-Tahar K, et al. Dynamics of meningococcal long-term carriage among university students and their implications for mass vacci-nation. J Clin Microbiol 2000; 38 (6): 2311-6
15. Virji M, Makepeace K, Ferguson DJ, et al. Meningococcal Opa and Opc proteins: their role in colonization and invasion of human epithelial and endothelial cells. Mol Microbiol 1993; 10 (3): 499-510
16. Stephens DS, Parley MM. Pathogenic events during infection of the human nasopharynx with Neisseria meningitidis and Haemophilus influenzae. Rev Infect Dis 1991; 13 (1): 22-33
17. Stephens DS. Uncloaking the meningococcus: dynamics of carriage and disease. Lancet 1999; 353 (9157): 941-2
18. Townsend R, Goodwin L, Stevanin TM, et al. Invasion by Neisseria meningitidis varies widely between clones and among nasopharyngeal mucosae derived from adult human hosts. Microbiology 2002; 148 (Pt 5): 1467-74
19. Kuppermann N. Occult bacteremia in young febrile children. Pediatr Clin North Am 1999; 46 (6): 1073-109
20. Tsolia MN, Theodoridou M, Tzanakaki G, et al. The evolving epidemiology of invasive meningococcal disease: a two-year prospective, population-based study in children in the area of Athens. FEMS Immunol Med Microbiol 2003; 36 (1-2): 87-94
21. Winstead JM, McKinsey DS, Tasker S, et al. Meningococcal pneumonia: characterization and review of cases seen over the past 25 years. Clin Infect Dis 2000; 30 (1): 87-94
22. Barquet N, Gasser I, Domingo P, et al. Primary meningococcal conjunctivitis: report of 21 patients and review. Rev Infect Dis 1990; 12 (5): 838-47
23. Kirsch EA, Barton RP, Kitchen L, et al. Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience. Pediatr Infect Dis J 1996; 15 (11): 967-78
24. Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med 2001; 344 (18): 1378-88
25. Nielsen HE, Koch C, Mansa B, et al. Complement and immunoglobulin studies in 15 cases of chronic meningococcemia: properdin deficiency and hypoimmunoglobulinemia. Scand J Infect Dis 1990; 22 (1): 31-6
26. Wong VK, Hitchcock W, Mason WH. Meningococcal infections in children: a review of 100 cases. Pediatr Infect Dis J 1989; 8 (4): 224-7
27. Connolly M, Noah N. Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993-6: European Meningitis Surveillance Group. Epidemiol Infect 1999; 122 (1): 41-9
28. Goldacre MJ, Roberts SE, Yeates D. Case fatality rates for meningococcal disease in an English population, 1963-98: database study. BMJ 2003; 327 (7415): 596-7
29. Booy R, Habibi P, Nadel S, et al. Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery. Arch Dis Child 2001; 85 (5): 386-90
30. Welch SB, Nadel S. Treating meningococcal infections in children. Hosp Med 2002; 63 (5): 268-73
31. Pollard AJ, Britto J, Nadel S, et al. Emergency management of meningococcal disease. Arch Dis Child 1999; 80 (3): 290-6
32. Erickson L, De Wals P. Complications and sequelae of meninococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis 1998; 26 (5): 1159-64
33. Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 1999; 180 (6): 1894-901
34. Harrison LH, Pass MA, Mendelsohn AB, et al. Invasive meningococcal disease in adolescents and young adults. JAMA 2001; 286 (6): 694-9
35. Nadel S, Macintosh I, Levin M. Evaluation of new treatments for meningococcal disease. In: Pollard A, Maiden M, editors. Meningococcal disease: methods in molecular medicine. Vol. 67. Totowa (NJ): Humana Press, 2001
36. Welch SB, Nadel S. Treatment of meningococcal infection. Arch Dis Child 2003; 88 (7): 608-14
37. Nicholson A, Lepow IH. Host defense against Neisseria meningitidis requires a complement-dependent bactericidal activity. Science 1979; 205 (4403): 298-9
38. Fijen CA, Kuijper EJ, te Bulte MT, et al. Assessment of complement deficiency in patients with meningococcal disease in The Netherlands. Clin Infect Dis 1999; 28 (1): 98-105
39. Orren A, Caugant DA, Fijen CA, et al. Characterization of strains of Neisseria meningitidis recovered from complement-sufficient and complement-deficient patients in the Western Cape Province, South Africa. J Clin Microbiol 1994; 32 (9): 2185-91
40. Hibberd ML, Sumiya M, Summerfield JA, et al. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease: Meningococcal Research Group. Lancet 1999; 353 (9158): 1049-53
41. Fijen CA, Kuijper EJ, Drogari-Apiranthitou M, et al. Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine. Clin Exp Immunol 1998; 114 (3): 362-9
42. Hobbs JR, Milner RD, Watt PJ. Gamma-M deficiency predisposing to meningococcal septicaemia. BMJ 1967; 4 (579): 583-6
43. Emonts M, Hazelzet JA, de Groot R, et al. Host genetic determinants of Neisseria meningitidis infections. Lancet Infect Dis 2003; 3 (9): 565-77
44. Locker GJ, Wagner A, Peter A, et al. Lethal Waterhouse-Friderichsen syndrome in post-traumatic asplenia. J Trauma 1995; 39 (4): 784-6
45. Bruce MG, Rosenstein NE, Capparella JM, et al. Risk factors for meningococcal disease in college students. JAMA 2001; 286 (6): 688-93
46. Harrison LH, Dwyer DM, Maples CT, et al. Risk of meningococcal infection in college students. JAMA 1999; 281 (20): 1906-10
47. Fischer M, Hedberg K, Cardosi P, et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis J 1997; 16 (10): 979-83
48. Jackson LA, Schuchat A, Reeves MW, et al. Serogroup C meningococcal outbreaks in the United States: an emerging threat. JAMA 1995; 273 (5): 383-9
49. Cartwright K, Noah N, Peltola H. Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines: report of a European advisory board meeting Vienna, Austria; 6-8 Oct 2000. Vaccine 2001; 19 (31): 4347-56
50. Peltola H, Kataja JM, Makela PH. Shift in the age-distribution of meningococcal disease as predictor of an epidemic? Lancet 1982; II (8298): 595-7
51. Diermayer M, Hedberg K, Hoesly F, et al. Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain. JAMA 1999; 281 (16): 1493-7
52. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001; 20 Suppl. 1: S58-67
53. Salleras L, Dominguez A, Prats G. Control of serogroup C meningococcal meningitis by mass vaccination in Catalonia (Spain). Vaccine 1999; 17 Suppl. 3: S56-60
54. Pereiro I, Diez-Domingo J, Morant A, et al. Epidemiological pattern of meningococcal disease in Valencia, Spain: impact of a mass immunization campaign with meningococcal C polysaccharide vaccine. Scand J Infect Dis 2001; 33 (8): 581-4
55. Levy-Bruhl D, Perrocheau A, Mora M, et al. Vaccination campaign following an increase in incidence of serogroup C meningococcal diseases in the department of Puy-de-Dome (France). Euro Surveill 2002; 7 (5): 74-6
56. Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol 2002; 51 (9): 717-22
57. Pollard AJ, Scheifele D. Meningococcal disease and vaccination in North America. J Paediatr Child Health 2001; 37 (5): S20-7
58. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995: active surveillance team. N Engl J Med 1997; 337 (14): 970-6
59. Hahne SJ, Gray SJ, Jean F, et al. W135 meningococcal disease in England and Wales associated with Hajj 2000 and 2001. Lancet 2002; 359 (9306): 582-3
60. Klaber R, Booy R, El Bashir H, et al. Sustained outbreak of W135 meningococcal disease in east London, UK [letter]. Lancet 2002; 360 (9333): 644
61. Wilder-Smith A, Barkham TM, Paton NI. Sustained outbreak of W135 meningococcal disease in east London, UK. Lancet 2002; 360: 644-5
62. Wilder-Smith A, Barkham TM, Earnest A, et al. Acquisition of W135 meningococcal carriage in Hajj pilgrims and transmission to household contacts: prospective study. BMJ 2002; 325: 365-6
63. Wilder-Smith A, Goh KT, Barkham T, et al. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin Infect Dis 2003; 36 (6): 679-83
64. Wilder-Smith A. W135 meningococcal carriage in association with the Hajj pilgrimage 2001: the Singapore experience. Int J Antimicrob Agents 2003; 21 (2): 112-5
65. Memish ZA. Meningococcal disease and travel. Clin Infect Dis 2002; 34 (1): 84-90
66. Stroffolini T, Angelini L, Galanti I, et al. The effect of meningococcal group A and C polysaccharide vaccine on nasopharyngeal carrier state. Microbiologica 1990; 13 (3): 225-9
67. Taha MK, Parent DC, Schlumberger M, et al. Neisseria meningitidis serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001; epidemics in Burkina Faso and Niger. J Clin Microbiol 2002; 40 (3): 1083-4
68. Ouedraogo-Traore R, Hoiby EA, Sanou I, et al. Molecular characteristics of Neisseria meningitidis strains isolated in Burkina Faso in 2001. Scand J Infect Dis 2002; 34 (11): 804-7
69. Woods CW, Armstrong G, Sackey SO, et al. Emergency vaccination against epidemic meningitis in Ghana: implications for the control of meningococcal disease in West Africa. Lancet 2000; 355 (9197): 30-3
70. World Health Organisation. Group A and C meningococcal vaccines. Wkly Epidemiol Rec 1999; 74: 297-303
71. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus: I. The role of humoral antibodies. J ExpMed 1969; 129 (6): 1307-26
72. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus: IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med 1969; 129 (6): 1367-84
73. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus: V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. J Exp Med 1969; 129 (6): 1385-95
74. Borrow R, Andrews N, Goldblatt D, et al. Serological basis for use of meningococ-cal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 2001; 69 (3): 1568-73
75. Santos GF, Deck RR, Donnelly J, et al. Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol 2001; 8 (3): 616-23
76. Trotter C, Borrow R, Andrews N, et al. Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine 2003; 21 (11-12): 1094-8
77. Artenstein MS, Gold R, Zimmerly JG, et al. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med 1970; 282 (8); 417-20
78. Biselli R, Fattorossi A, Matricardi PM, et al. Dramatic reduction of meningococcal meningitis among military recruits in Italy after introduction of specific vaccination. Vaccine 1993; 11 (5): 578-81
79. Stroffolini T. Vaccination campaign against meningococcal disease in army recruits in Italy. Epidemiol Infect 1990; 105 (3): 579-83
80. Makela PH, Kayhty H, Weckstrom P, et al. Effect of group A meningococcal vaccine in army recruits in Finland. Lancet 1975; II (7941): 883-6
81. Peltola H, Makela H, Kayhty H, et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med 1977; 297 (13): 686-91
82. De Wals P, De Serres G, Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA 2001; 285 (2): 177-81
83. Ball R, Braun MM, Mootrey GT. Safety data on meningococcal polysaccharide vaccine from the Vaccine Adverse Event Reporting System. Clin Infect Dis 2001; 32 (9): 1273-80
84. Brundage JF, Ryan MA, Feighner BH, et al. Meningococcal disease among United States military service members in relation to routine uses of vaccines with different serogroup-specific components, 1964-1998. Clin Infect Dis 2002; 35 (11): 1376-81
85. Center for Disease Control and Prevention. Meningococcal disease and college students: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49 (RR-7): 13-20
86. Patel M, Lee CK. Polysaccharide vaccines for preventing serogroup A meningococcal meningitis. Cochrane Database Syst Rev 2001; (3): CD001093
87. De Wals P, Dionne M, Douville-Fradet M, et al. Impact of a mass immunization campaign against serogroup C meningococcus in the Province of Quebec, Canada. Bull World Health Organ 1996; 74 (4): 407-11
88. Lennon D, Gellin B, Hood D, et al. Successful intervention in a group A meningococcal outbreak in Auckland, New Zealand. Pediatr Infect Dis J 1992; 11 (8): 617-23
89. Espin RI, Garcia-Fulgueiras A, Navarro Alonso JA, et al. Seroconversion and duration of immunity after vaccination against group C meningococcal infection in young children. Vaccine 2000; 18 (24): 2656-60
90. Gold R, Lepow ML, Goldschneider I, et al. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis 1979; 140 (5): 690-7
91. Borrow R, Richmond P, Kaczmarski EB, et al. Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococcal A/C polysaccharide vaccine. FEMS Immunol Med Microbiol 2000; 28 (1): 79-85
92. Harris SL, King WJ, Ferris W, et al. Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine. Infect Immun 2003; 71 (1): 275-86
93. Gold R, Lepow ML, Goldschneider I, et al. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest 1975; 56 (6): 1536-47
94. Gold R, Lepow ML, Goldschneider I, et al. Antibody responses of human infants to three doses of group A Neisseria meningitidis polysaccharide vaccine administered at two, four, and six months of age. J Infect Dis 1978; 138 (6): 731-5
95. Robbins JB, Towne DW, Gotschlich EC, et al. 'Love's labours lost': failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa. Lancet 1997; 350: 880-2
96. Miller MA, Wenger J, Rosenstein N, et al. Evaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa. Pediatr Infect Dis J 1999; 18 (12): 1051-9
97. Robbins JB, Schneerson R, Gotschlich EC. A rebuttal: epidemic and endemic meningococcal meningitis in sub-Saharan Africa can be prevented now by routine immunization with group A meningococcal capsular polysaccharide vaccine. Pediatr Infect Dis J 2000; 19 (10): 945-53
98. Kayhty H, Karanko V, Peltola H, et al. Serum antibodies to capsular polysaccharide vaccine of group A Neissera meningitidis followed for three years in infants and children. J Infect Dis 1980; 142 (6): 861-8
99. MacDonald NE, Halperin SA, Law BJ, et al. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA 1998; 280 (19): 1685-9
100. Leach A, Twumasi PA, Kumah S, et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis 1997; 175 (1): 200-4
101. Richmond P, Kaczmarski E, Borrow R, et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 2000; 181 (2): 761-4
102. MacLennan J, Obaro S, Decks J, et al. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy. J Infect Dis 2001; 183 (1): 97-104
103. Borrow R, Southern J, Andrews N, et al. Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naive controls. Vaccine 2001; 19 (23-24): 3043-50
104. MacLennan J, Obaro S, Deeks J, et al. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. Vaccine 1999; 17 (23-24): 3086-93
105. Borrow R, Goldblatt D, Andrews N, et al. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children. J Infect Dis 2001; 184 (3): 377-80
106. Granoff DM, Gupta RK, Belshe RB, et al. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 1998; 178 (3): 870-4
107. Heath PT. Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Pediatr Infect Dis J 1998; 17 (9 Suppl.): S117-22
108. Wenger JD. Epidemiology of Haemophilus influenzae type b disease and impact of Haemophilus influenzae type b conjugate vaccines in the United States and Canada. Pediatr Infect Dis J 1998; 17 (9 Suppl.): S132-6
109. Ahmad H, Chapnick EK. Conjugated polysaccharide vaccines. Infect Dis Clin North Am 1999; 13 (1): 113-33, vii
110. Anderson EL, Bowers T, Mink CM, et al. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect Immun 1994; 62 (8): 3391-5
111. Lieberman JM, Chiu SS, Wong VK, et al. Safety and immunogenicity of a serogroup A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children: a randomized controlled trial. JAMA 1996; 275 (19): 1499-503
112. Twumasi Jr PA, Kumah S, Leach A, et al. A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis 1995; 171 (3): 632-8
113. Harris SL, Finn A, Granoff DM. Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidis-diphlheria toxoid conjugate vaccine and by a polysaccharide vaccine. Infect Immun 2003; 71 (6): 3402-8
114. MacLennan JM, Shackley F, Heath PT, et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA 2000; 283 (21): 2795-801
115. Richmond P, Borrow R, Findlow J, et al. Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains. Infect Immun 2001; 69 (4): 2378-82
116. Richmond P, Goldblatt D, Fusco PC, et al. Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 1999; 18 (7-8): 641-6
117. Campagne G, Garba A, Fabre P, et al. Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger. Pediatr Infect Dis J 2000; 19 (2): 144-50
118. Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants. Pediatr Infect Dis J 2001; 20 (2): 153-9
119. Bramley JC, Hall T, Finn A, et al. Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age. Vaccine 2001; 19 (20-22); 2924-31
120. Choo S, Zuckerman J, Goilav C, et al. Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine compared with a group A + C meningococcal polysaccharide vaccine in adolescents in a randomised observer-blind controlled trial. Vaccine 2000; 18 (24): 2686-92
121. Richmond P, Borrow R, Goldblatt D, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 2001; 183 (1): 160-3
122. Richmond P, Borrow R, Miller E, et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 1999; 179 (6): 1569-72
123. Ramsay ME, Andrews NJ, Trotter CL, et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003; 326 (7385): 365-6
124. Borrow R. Meningococcal group C conjugate vaccination in England and Wales: an update 2002. Data presented at 20th Annual Meeting of the European Society of Paediatric Infectious Diseases (ESPID); 2002 May 29-31; Vilnius
125. Bose A, Coen P, Tully J, et al. Effectiveness of meningococcal C conjugate vaccine in teenagers in England. Lancet 2003; 361 (9358): 675-6
126. Department of Health. Extending meningitis C vaccine to 20-24 year olds: from the chief medical officer, the chief nursing officer, and the chief pharmacist 2002, 4 January. London: Department of Health, 2002
127. McVernon J, MacLennan J, Pollard AJ, et al. Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years. Pediatr Infect Dis J 2003; 22 (7): 659-61
128. Maiden MC, Spratt BG. Meningococcal conjugate vaccines: new opportunities and new challenges. Lancet 1999; 354: 615-6
129. Swartley JS, Marfin AA, Edupuganti S, et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci U S A 1997; 94 (1): 271-6
130. Vogel U, Claus H, Frosch M. Rapid serogroup switching in Neisseria meningitidis. N Engl J Med 2000; 342: 219-20
131. Shlush LI, Behar DM, Zelazny A, et al. Molecular epidemiological analysis of the changing nature of a meningococcal outbreak following a vaccination campaign. J Clin Microbiol 2002; 40 (10): 3565-71
132. Perez-Trallero E, Vicente D, Montes M, et al. Positive effect of meningococcal C vaccination on serogroup replacement in Neisseria meningitidis [letter]. Lancet 2002; 360 (9337): 953
133. PHLS-Guidance document. Surveillance of impact of meningococcal serogroup C conjugate vaccination programme in England and Wales and protocol for investigation of vaccine failures [online]. Available from URL: http://www.hpa.org.uk/infections/topics_az/meningo/advice/mensurvw99.pdf [Accessed 2004 Aug 9]
134. Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002; 359 (9320): 1829-31
135. Ruggeberg J, Heath PT. Safety and efficacy of meningococcal group C conjugate vaccines. Expert Opin Drug Saf 2003; 2 (1): 7-19
136. English M, MacLennan JM, Bowen-Morris JM, et al. A randomised, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infants. Vaccine 2000; 19 (9-10): 1232-8
137. Fairley CK, Begg N, Borrow R, et al. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J Infect Dis 1996; 174 (6): 1360-3
138. Lakshman R, Jones I, Walker D, et al. Safety of a new conjugate meningococcal C vaccine in infants. Arch Dis Child 2001; 85 (5): 391-7
139. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children: Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19 (3): 187-95
140. Medicines Control Agency. Report of the Committee on Safety of Medicines Expert Working Group on Meningococcal Group C Conjugate Vaccines (2002) [online]. Available from URL: http://www.mca.gov.uk/ourwork/monitorsafe-qualmed/ safetymessages/mencwgreport.pdf [Accessed 2004 Aug 9]
141. De Wals P, Nguyen VH, Erickson L, et al. Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease. Vaccine 2004 Mar 12; 22 (9-10): 1233-40
142. Borrow R, Goldblatt D, Finn A, et al. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus conjugate vaccine in infants in the United Kindgdom. Infect Immun 2003; 71 (10): 5549-55
143. Rennels M, King Jr J, Ryall R, et al. Dose escalation, safety and immunogenicity study of a tetravalent meninogococcal polysaccharide diphtheria conjugate vaccine in toddlers. Pediatr Infect Dis J 2002; 21 (10): 978-9
144. Lingappa JR, Rosenstein N, Zell ER, et al. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States. Vaccine 2001; 19 (31): 4566-75
145. Jaccard Ruedin H, Ess S, Zimmermann HP, et al. Invasive meningococcal and pneumococcal disease in Switzerland: cost-utility analysis of different vaccine strategies. Vaccine 2003; 21: 4145-52
146. Vermont C, van den Dobbelsteen G. Neisseria meningitidis serogroup B: laboratory correlates of protection. FEMS Immunol Med Microbiol 2002; 34 (2): 89-96
147. Williams JN, Jones GR, Christodoulides M, et al. Serological correlates of protection against meningococci in a cohort of university students, before and during an outbreak of serogroup C infection. J Infect 2003; 187: 1433-41
148. Boslego J, Garcia J, Cruz C, et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15: Pl.3) outer membrane protein vaccine in Iquique, Chile: Chilean National Committee for Meningococcal Disease. Vaccine 1995; 13 (9): 821-9
149. Pollard AJ, Galassini R, van der Voort EM, et al. Humoral immune responses to Neisseria meningitidis in children. Infect Immun 1999; 67 (5): 2441-51
150. Milagres LG, Ramos SR, Sacchi CT, et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun 1994; 62 (10): 4419-24
151. de Moraes JC, Perkins BA, Camargo MC, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992; 340 (8827): 1074-8
152. Holst J, Feiring B, Fuglesang JE, et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003; 21 (7-8): 734-7
153. Perkins BA, Jonsdottir K, Briem H, et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis 1998; 177 (3): 683-91
154. Zollinger WD, Mandrell RE. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect Immun 1983; 40 (1): 257-64
155. Finne J, Bitter-Suermann D, Goridis C, et al. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 1987; 138 (12): 4402-7
156. Devi SJ, Zollinger WD, Snoy PJ, et al. Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys. Infect Immun 1997; 65 (3): 1045-52
157. Bartoloni A, Norelli F, Ceccarini C, et al. Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide. Vaccine 1995; 13 (5): 463-70
158. Jennings HJ, Roy R, Gamian A. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J Immunol 1986; 137 (5): 1708-13
159. Jennings HJ, Gamian A, Ashton FE. N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis. J Exp Med 1987; 165 (4): 1207-11
160. Fusco PC, Michon F, Tai JY, et al. Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates. J Infect Dis 1997; 175 (2): 364-72
161. Granoff DM, Bartoloni A, Ricci S, et al. Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J Immunol 1998; 160 (10): 5028-36
162. Sierra GV, Campa HC, Varcacel NM, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991; 14 (2): 195-207
163. Noronha CP, Struchiner CJ, Halloran ME. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study. Int J Epidemiol 1995; 24 (5): 1050-7
164. Bjune G, Hoiby EA, Gronnesby JK, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991; 338 (8775): 1093-6
165. Tappero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999; 281 (16): 1520-7
166. Rosenqvist E, Hoiby EA, Wedege E, et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 1995; 63 (12): 4642-52
167. Milagres LG, Gorla MC, Sacchi CT, et al. Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine. Infect Immun 1998; 66 (10): 4755-61
168. Van Der LP, van der BJ, Poolman JT. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine 1995; 13 (4): 401-7
169. Tondella ML, Popovic T, Rosenstein NE, et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States: the Active Bacterial Core Surveillance Team. J Clin Microbiol 2000; 38 (9): 3323-8
170. Cartwright K, Morris R, Rumke H, et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 1999; 17 (20-21): 2612-9
171. de Kleijn ED, de Groot R, Labadie J, et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine 2000; 18 (15): 1456-66
172. Longworth E, Borrow R, Goldblatt D, et al. Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants. Vaccine 2002; 20 (19-20): 2592-6
173. van der EA, Hopman CT, Keijzers WC, et al. Outbreak of meningococcal disease caused by PorA-deficient meningococci. J Infect Dis 2003; 187 (5): 869-71
174. Gold R, Goldschneider I, Lepow ML, et al. Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J Infect Dis 1978; 137 (2): 112-21
175. Olsen SF, Djurhuus B, Rasmussen K, et al. Pharyngeal carriage of Neisseria meningitidis and Neisseria lactamica in households with infants within areas with high and low incidences of meningococcal disease. Epidemiol Infect 1991; 106 (3): 445-57
176. Troncoso G, Sanchez S, Criado MT, et al. Analysis of Neisseria lactamica antigens putatively implicated in acquisition of natural immunity to Neisseria meningitidis. FEMS Immunol Med Microbiol 2002; 34 (1): 9-15
177. Troncoso G, Sanchez S, Moreda M, et al. Antigenic cross-reactivity between outer membrane proteins of Neisseria meningitidis and commensal Neisseria species. FEMS Immunol Med Microbiol 2000; 27 (2): 103-9
178. Cann KJ, Rogers TR. Detection of antibodies to common antigens of pathogenic and commensal Neisseria species. J Med Microbiol 1989; 30 (1): 23-31
179. Sanchez S, Troncoso G, Criado MT, et al. Interspecific neisserial high molecular weight proteins able to induce natural immunity responses are strongly correlated with in vitro bactericidal activity. Vaccine 2002; 20 (23-24): 2964-71
180. Sanchez S, Troncoso G, Criado MT, et al. In vitro induction of memory-driven responses against Neisseria meningitidis by priming with Neisseria lactamica. Vaccine 2002; 20 (23-24): 2957-63
181. Oliver KJ, Reddin KM, Bracegirdle P, et al. Neisseria lactamica protects against experimental meningococcal infection. Infect Immun 2002; 70 (7): 3621-6
182. Cornelissen CN, Kelley M, Hobbs MM, et al. The transform receptor expressed by gonococcal strain FA1090 is required for the experimental infection of human male volunteers. Mol Microbiol 1998; 27 (3): 611-6
183. Schryvers AB, Stojiljkovic I. Iron acquisition systems in the pathogenic Neisseria. Mol Microbiol 1999; 32 (6): 1117-23
184. Johnson AS, Gorringe AR, Mackinnon FG, et al. Analysis of the human Ig isotype response to lactoferrin binding protein A from Neisseria meningitidis. FEMS Immunol Med Microbiol 1999; 25 (4): 349-54
185. Johnson AS, Gorringe AR, Fox AJ, et al. Analysis of the human Ig isotype response to individual transferrin binding proteins A and B from Neisseria meningitidis. FEMS Immunol Med Microbiol 1997; 19 (2): 159-67
186. Pettersson A, Prinz T, Umar A, et al. Molecular characterization of LbpB, the second lactoferrin-binding protein of Neisseria meningitidis. Mol Microbiol 1998; 27 (3): 599-610
187. Gomez JA, Criado MT, Ferreiros CM. Bactericidal activity of antibodies elicited against the Neisseria meningitidis 37-kDa ferric binding protein (FbpA) with different adjuvants. FEMS Immunol Med Microbiol 1998; 20 (1): 79-86
188. Ala'Aldeen DA, Davies HA, Borriello SP. Vaccine potential of meningococcal FrpB: studies on surface exposure and functional attributes of common epitopes. Vaccine 1994; 12 (6): 535-41
189. Ala'Aldeen DA. Transferrin receptors of Neisseria meningitidis: promising candidates for a broadly cross-protective vaccine. J Med Microbiol 1996; 44 (4): 237-43
190. Ala'Aldeen DA, Stevenson P, Griffiths E, et al. Immune responses in humans and animals to meningococcal transferrin-binding proteins: implications for vaccine design. Infect Immun 1994; 62 (7): 2984-90
191. Lehmann AK, Gorringe AR, Reddin KM, et al. Human opsonins induced during meningococcal disease recognize transferrin binding protein complexes. Infect Immun 1999; 67 (12): 6526-32
192. West D, Reddin K, Matheson M, et al. Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection. Infect Immun 2001; 69 (3): 1561-7
193. Danve B, Lissolo L, Mignon M, et al. Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals. Vaccine 1993; 11 (12): 1214-20
194. Ala'Aldeen DA, Borriello SP. The meningococcal transferrin-binding proteins 1 and 2 are both surface exposed and generate bactericidal antibodies capable of killing homologous and heterologous strains. Vaccine 1996; 14 (1): 49-53
195. Rokbi B, Renauld-Mongenie G, Mignon M, et al. Allelic diversity of the two transferrin binding protein B gene isotypes among a collection of Neisseria meningitidis strains representative of serogroup B disease: implication for the composition of a recombinant TbpB-based vaccine. Infect Immun 2000; 68 (9): 4938-47
196. Martin D, Cadieux N, Hamel J, et al. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exp Med 1997; 185 (7): 1173-83
197. Moe GR, Tan S, Granoff DM. Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect Immun 1999; 67 (II): 5664-75
198. Moe GR, Zuno-Mitchell P, Lee SS, et al. Functional activity of anti-neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B. Infect Immun 2001; 69 (6): 3762-71
199. Hadi HA, Wooldridge KG, Robinson K, et al. Identification and characterization of App: an immunogenic autotransporter protein of Neisseria meningitidis. Mol Microbiol 2001; 41 (3): 611-23
200. Serruto D, Adu-Bobie J, Scarselli M, et al. Neisseria meningitidis App, a new adhesin with autocatalytic serine protease activity. Mol Microbiol 2003; 48 (2): 323-34
201. Thompson EA, Feavers IM, Maiden MC. Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology 2003; 149 (Pt 7): 1849-58
202. de Jonge MI, Vidarsson G, van Dijken HH, et al. Functional activity of antibodies against the recombinant OpaJ protein from Neisseria meningitidis. Infect Immun 2003; 71 (5): 2331-40
203. Jolley KA, Appleby L, Wright JC, et al. Immunization with recombinant Ope outer membrane protein from Neisseria meningitidis: influence of sequence variation and levels of expression on the bactericidal immune response against meningococci. Infect Immun 2001; 69 (6): 3809-16
204. Stephens DS, Whitney AM, Rothbard J, et al. Pili of Neisseria meningitidis: analysis of structure and investigation of structural and antigenic relationships to gonococcal pili. J Exp Med 1985; 161 (6): 1539-53
205. Wright JC, Williams JN, Christodoulides M, et al. Immunization with the recombinant PorB outer membrane protein induces a bactericidal immune response against Neisseria meningitidis. Infect Immun 2002; 70 (8): 4028-34
206. Munkley A, Tinsley CR, Virji M, et al. Blocking of bactericidal killing of Neisseria meningitidis by antibodies directed against class 4 outer membrane protein. Microb Pathog 1991; 11 (6): 447-52
207. Rosenqvist E, Musacchio A, Aase A, et al. Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis. Infect Immun 1999; 67 (3): 1267-76
208. Parkhill J, Achtman M, James KD, et al. Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature 2000; 404 (6777): 502-6
209. Tettelin H, Saunders NJ, Heidelberg J, et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 2000; 287 (5459): 1809-15
210. Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000; 287 (5459): 1816-20
211. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 2001; 19 (17-19): 2688-91
212. Poolman J, Berthet FX. Alternative vaccine strategies to prevent serogroup B meningococcal diseases. Vaccine 2001; 20 Suppl. 1: S24-6
213. Saunders NJ, Jeffries AC, Peden JF, et al. Repeat-associated phase variable genes in the complete genome sequence of Neisseria meningitidis strain MC58. Mol Microbiol 2000; 37 (1): 207-15
214. Kurz S, Hubner C, Aepinus C, et al. Transcriptome-based antigen identification for Neisseria meningitidis. Vaccine 2003; 21 (7-8): 768-75
215. ed JS, Makepeace K, Jennings MP, et al. Conservation and accessibility of an inner core lipopolysaccharide epitope of Neisseria meningitidis. Infect Immun 1999; 67 (10): 5417-26
216. Plested JS, Harris SL, Wright JC, et al. Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia. J Infect Dis 2003; 187 (8): 1223-34